Ray Dalio's MRNA Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 222,210 shares of Moderna, Inc. (MRNA) worth $5.74 M, representing 0.02% of the portfolio. First purchased in 2021-Q3, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in MRNA, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 590,473 shares. Largest reduction occurred in Q3 2025, reducing 383,572 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Moderna (MRNA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Moderna (MRNA) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2021 | +8,309 | New Buy | 8,309 | $384.88 |
| Q4 2021 | -4,670 | Reduce 56.20% | 3,639 | $253.92 |
| Q1 2022 | +43,042 | Add 1182.80% | 46,681 | $172.25 |
| Q2 2022 | +202,476 | Add 433.74% | 249,157 | $142.85 |
| Q3 2022 | -231,722 | Reduce 93.00% | 17,435 | $118.27 |
| Q4 2022 | -9,758 | Reduce 55.97% | 7,677 | $179.62 |
| Q1 2023 | -2,301 | Reduce 29.97% | 5,376 | $153.58 |
| Q2 2023 | +25,489 | Add 474.13% | 30,865 | $121.50 |
| Q3 2023 | -30,865 | Sold Out | 30,865 | $0.00 |
| Q2 2024 | +15,309 | New Buy | 15,309 | $118.75 |
| Q3 2024 | -15,309 | Sold Out | 15,309 | $0.00 |
| Q4 2024 | +605,782 | New Buy | 605,782 | $41.58 |
| Q1 2025 | -605,782 | Sold Out | 605,782 | $0.00 |
| Q3 2025 | +222,210 | New Buy | 222,210 | $25.83 |
Ray Dalio's Moderna Investment FAQs
Ray Dalio first purchased Moderna, Inc. (MRNA) in Q3 2021, acquiring 8,309 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Moderna, Inc. (MRNA) for 17 quarters since Q3 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to Moderna, Inc. (MRNA) was in Q4 2024, adding 605,782 shares worth $25.19 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 222,210 shares of Moderna, Inc. (MRNA), valued at approximately $5.74 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Moderna, Inc. (MRNA) represents approximately 0.02% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in Moderna, Inc. (MRNA) was 605,782 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.